Clinical trials
Autologous Hematopoietic Stem Cell Transplantation clinical trials
Below are recruiting autologous hematopoietic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 126 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04356287RecruitingPhase 1/Phase 2
Cord cell treatment for severe systemic sclerosis symptoms
This early-phase study tests whether umbilical cord-derived “cord blood–type” cells can reduce or improve severe systemic sclerosis (a type of hardening/scarring disease of connective tissue). It may help people whose current standard treatments haven’t worked or caused side effects.
Montreal, QuebecAges 18 years+ - NCT06442761RecruitingPhase 1
Stem cell collection for sickle cell disease using motixafortide
This trial tests a drug called motixafortide that helps move stem cells from your bone marrow into your blood so they can be collected for future gene therapy. It is for adults with severe sickle cell disease who may benefit from this treatment approach.
Birmingham, AlabamaAges 18 years+ - NCT05388695RecruitingPhase 1
Testing dual-target CAR T cells for B-cell blood cancers
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
Wuhan, HubeiAges 18–70 - NCT05682144RecruitingPhase 1
Cell therapy for MPS I to improve immune function
This Phase 1 study tests an engineered cell therapy made to help the body in people with MPS I (Hurler-Scheie or Scheie). It is early-stage research, so the main goal is to learn about safety and the best way to treat.
Oakland, CaliforniaAges 10 years+ - NCT07680803RecruitingPhase 2
Gene therapy for transfusion-dependent beta-thalassemia
This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.
Rome, LazioAges 3–35 - NCT07413809RecruitingPhase 3
Preventing nausea after stem cell transplant: olanzapine vs dexamethasone
This trial compares two anti-nausea drug regimens (one with olanzapine, one with dexamethasone) to prevent delayed nausea and vomiting after a stem cell transplant for multiple myeloma. It aims to find which is better at controlling these side effects.
Ningbo, ZhejiangAges 18–65 - NCT05294055RecruitingPhase 2
Mecapegfilgrastim to help collect stem cells for transplant
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
Hefei, AnhuiAges 18–65 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07101445RecruitingPhase 4
Comparing steroids to prevent reactions to motixafortide in multiple myeloma
This trial tests two different steroid medicines (methylprednisolone and dexamethasone) to see which works better at preventing side effects from motixafortide, a drug used to help collect stem cells for a stem cell transplant in people with multiple myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT06514508RecruitingPhase 3
Stem cell collection with motixafortide and G-CSF for multiple myeloma
This trial tests a new drug, motixafortide, combined with a standard growth factor (G-CSF) to help collect stem cells for a transplant in people with multiple myeloma. It may be a good option if your myeloma is in remission and you have not had a stem cell transplant before.
Beijing, Beijing MunicipalityAges 18–78 - NCT05618041Recruiting
CAR-T treatment trial for relapsed or hard-to-treat blood cancers
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Taiyuan, ShanxiAges 14–75 - NCT06904066RecruitingPhase 1
Personalized T cell therapy for blood cancers
This trial tests a treatment that takes your own immune cells, modifies them to attack cancer cells, and gives them back to you. It is for people with certain blood cancers who have specific gene changes.
Bethesda, MarylandAges 18–120 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years - NCT06253494RecruitingPhase 1/Phase 2
Combination therapy trial for advanced endometrial cancer
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
Bethesda, MarylandAges 18–120 - NCT06999031RecruitingEarly Phase 1
CG-105-12 for relapsed/refractory multiple myeloma
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
Nanchang, JiangxiAges 18–75 - NCT07162012RecruitingEarly Phase 1
Cell therapy for EBV-positive lymphoma
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
ShanghaiAges 18–70 - NCT06560827RecruitingPhase 1
CAR-T Cells for Liver Cancer After Surgery
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
BeijingAges 18–75 - NCT06614686RecruitingPhase 1
CAR-T therapy for advanced head and neck cancer
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
ShanghaiAges 18–70 - NCT05546723RecruitingPhase 1
Study drug for multiple myeloma after several prior treatments
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Cleveland, OhioAges 18 years+ - NCT07179484Recruiting
Study of CT041 for advanced stomach or junction cancer after first treatment
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
BeijingAges 18–75 - NCT05979363RecruitingPhase 2
CAR-T cell therapy for plasma cell leukemia patients
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
TianjinAges 18–75 - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT07123545RecruitingPhase 1/Phase 2
Personalized T-cell therapy for advanced liver cancer
This trial tests a personalized treatment using your own immune cells (T-cells) trained to attack specific markers on your liver cancer. It is for people with advanced liver cancer that has worsened after at least two prior treatments and who have tumor tissue available for genetic testing.
Hangzhou, ZhejiangAges 18–75
Hear when a new Autologous Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autologous hematopoietic stem cell transplantation?
- Yes. Clin2 currently lists 126 recruiting autologous hematopoietic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autologous hematopoietic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autologous hematopoietic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Stem Cell Transplantation
- Hematopoietic Stem Cell Transplant
- Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.